HealthtechBio Tech/Life SciencesAI/MLDeep TechB2B1-5 employees
Actively Raising
About
A Software-as-a-Medical-Device (SaMD) platform that predicts metastasis, recurrence, treatment response, and toxicity from biopsy in 5 days using quantum-enhanced precision oncology.
Traction & Metrics
Users & Clients
3
Clients
Fundraising
$280K
Previous Round
Team
Ashkan
CEO
Arvin
COO
Products
SequestOne
Quantum-enhanced precision oncology platform that predicts metastasis, recurrence, treatment response, and toxicity from biopsy samples in 5 days. Delivers clinical readouts including metastasis risk with organ mapping, recurrence risk with ctDNA monitoring cadence, treatment ranking for pathologic complete response and disease-free survival, and toxicity/DPYD safety predictions.
Click to read more